INVESTABOT
Equity Research
XNAS · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: MiMedx posted Q1 2026 revenue of $59 million, down 33.1% from $88.2 million in the year-ago quarter, as sweeping Medicare reimbursement changes hit the wound care market hard.
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 11,333,771 | $76,729,630 | — | 2/12/2026 |
| BlackRock | 9,313,838 | $64,544,898 | — | 8/13/2024 |
| Vanguard Group | 7,184,262 | $48,637,455 | — | 1/29/2026 |
| BlackRock | 11,911,300 | $47,049,635 | 5.1% | 5/13/2026 |
| BlackRock | 12,154,466 | $46,794,695 | 2.0% | 8/7/2026 |
| State Street | 3,813,796 | $25,819,399 | — | 2/13/2026 |
| State Street | 5,578,920 | $21,478,842 | 10.3% | 8/7/2026 |
| State Street | 5,056,801 | $19,974,364 | 32.6% | 5/15/2026 |
| Renaissance Technologies | 2,467,065 | $16,702,030 | — | 2/12/2026 |
| Renaissance Technologies | 3,019,871 | $11,928,490 | 22.4% | 5/14/2026 |
| Goldman Sachs | 2,665,562 | $10,262,414 | 124.8% | 8/14/2026 |
| AQR Capital | 2,467,005 | $9,497,969 | 170.3% | 8/14/2026 |
| Renaissance Technologies | 2,444,230 | $9,410,285 | -19.1% | 8/13/2026 |
| Goldman Sachs | 1,090,385 | $7,381,906 | — | 3/25/2026 |
| Morgan Stanley | 727,783 | $4,927,091 | — | 5/27/2026 |
| Goldman Sachs | 1,185,561 | $4,682,966 | 8.7% | 5/15/2026 |
| Millennium Management | 619,921 | $4,196,865 | — | 2/17/2026 |
| Morgan Stanley | 1,043,286 | $4,016,652 | 28.4% | 8/13/2026 |
| AQR Capital | 912,728 | $3,605,275 | 123.8% | 5/15/2026 |
| Citadel Advisors | 844,138 | $3,249,931 | 3.9% | 8/14/2026 |